The burgeoning popularity of semaglutide , initially for diabetes , is creating significant attention within the UK , prompting a notable shift in hormone trends. Availability these medications remains a complex landscape, with NHS provision currently limited and independent providers offering treatment at a higher cost . Questions are being raised